Latest Articles
-
Medtronic: Good Symplicity Test Results But FDA Approval Not Close
Medtronic (NYSE:MDT) has reported impressive one-year results from its Symplicity HTN-2 study for its renal denervation device (a radiotherapy-based system to treat high blood pressure), Symplicity. According to the medical device maker, hyperten...
-
14 Best Dividend Aristocrats Growth Stock Picks For 2013
Submitted by Dividend Yield as part of our contributors program . Best Dividend Aristocrats stock picks for 2013 originally published at “ long-term-investments.blogspot.com ” Buying high quality stocks at cheap prices is one of th...
-
Weekly Healthcare Summary: Abbott, Pfizer, JNJ, Boston Scientific, Medtronic and Roche Holdings
We plan to release a weekly note on the recent happenings in the healthcare space impacting healthcare companies under our coverage. Below we summarize a few such events related to Abbott Labs (NYSE:ABT), Pfizer (NYSE:PFE), Johnson & Johnson ...
-
Medtronic Could Gain From St. Jude Issues, China Expansion
Medtronic ‘s (NYSE:MDT) largest competitor in the Cardiac Rhythm Management (Pacemakers/ Defibrillators or CRDM) market, St. Jude, is facing the threat of another recall (Read Boston Scientific Could Benefit From St. Jude Medical’s Tr...
-
Winners And Losers From Health Care Reform
Submitted by Investing Daily as part of our contributors program . While this year’s presidential election was critical to the economic future of the US, it posed particularly significant ramifications for the health care sector and its ...
-
3 Picks Of The Best Dividend Growth Stocks From Last Week
Submitted by Dividend Yield as part of our contributors program . Stocks with biggest dividend hikes from last week; originally published at Dividend Yield – Stock, Capital, Investment . Here is a current sheet of companies that have announced...
-
ChromaDex Is the Next Martek
Submitted by Sarah Harris as part of our contributors program . Most investors do not understand ChromaDex (CDXC) and are severely misinterpreting its progression as a company. Looking at the last decade of the ChromaDex’s existence as a l...
-
Medtronic’s Results Were Solid Despite Business and Currency Challanges
Medtronic (NYSE:MDT) announced its second quarter earnings for fiscal 2013 on Tuesday, registering a decline in its key pacemakers & defibrillators and spinal divisions, in-line with our expectations. However, growth in cardiovascular, diabet...
-
Expecting Mixed Results From Medtronic Earnings
Medtronic (NYSE:MDT) is set to announce its Q2 earnings for fiscal 2013 on Tuesday, November 20. We expect its key pacemakers & defibrillators and spinal divisions to register a decline in revenues. However, growth in cardiovascular, diabete...
-
Medtronic Struggles With Infuse Product Issues And Weak Business Environment
It seems the worst is not yet over for Medtronic (NYSE:MDT) as a U.S. Senate investigation found that the company manipulated journals data relating to its INFUSE bone graft, a key product of its spinal division. Medtronic has been losing market ...
-
Casey Analyst Forecasts Explosive Biotech Growth
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by The Life Sciences Report (10/11/12) The myth of technology, whether for smartphones or cancer treatments, is that the next big thin...
-
How To Justify Medtronic Reaching $50
Medtronic ‘s (NYSE:MDT) stock has appreciated 15% this year and is approaching our $45 price estimate following several product launches and the announcement to acquire Chinese medical devices maker China Kanghui Holdings. (Read Medtronic P...
-
Medtronic Pays Princely Sum For Greater China Access With Acquisition
Medtronic (NYSE:MDT) is acquiring Chinese medical devices maker China Kanghui Holdings in a move that could strengthen its foothold in the rapidly-growing Chinese device market. Medtronic will shell out approximately $800 million dollars on the d...
-
How An Alzheimer Deal Could Benefit Medtronic And Roche
Medtronic (NYSE:MDT) is looking to partner with pharmaceutical giants as the company believes its drug delivery pump could increase the effectiveness of upcoming Alzheimer treatments. With its strong Alzheimer drug pipeline and no major competito...
-
Medtronic: Revised $45 Price Estimate Following Earnings
Medtronic (NYSE:MDT) announced its quarterly earnings for Q1 2013 on August 21, registering a decline in its key Pacemakers & Defibrillators and Spinal divisions, in line with our expectations. However, growth in Cardiovascular, Diabetes and ...
